Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study
View Full Paper
Ask AI
Bookmark
Share
Key result
Febuxostat treatment for 24 months significantly prevented the worsening of left ventricular diastolic function, as measured by the change in E/e', compared to lifestyle modification alone in patients with asymptomatic hyperuricemia.
Why the study?
Hyperuricemia is associated with increased cardiovascular risk, and antihyperuricemic agents may influence cardiac function, but the effect of febuxostat on diastolic function remained unclear.
Does febuxostat prevent the progression of left ventricular diastolic dysfunction in patients with asymptomatic hyperuricemia?
Population
65 patients with asymptomatic hyperuricemia with complete echocardiographic data
Comparison
Add-on febuxostat treatment vs control with lifestyle modification alone
Design
Prespecified randomized subanalysis
Follow-up
24 months
Authors
Discussion
Loading...
Member takes
Implication
Supports febuxostat to preserve diastolic function in asymptomatic hyperuricemia; extends prior gout trials to primary prevention.
Study Design
Type
RCT (n=65)
Blinding
Open-label, blinded-endpoint
Randomization
1:1
Multicenter
Yes
Structured PICO
Does febuxostat prevent the progression of left ventricular diastolic dysfunction in patients with asymptomatic hyperuricemia?
P
Population
65 Japanese adults with asymptomatic hyperuricemia (median age 71, 20% female) were followed for 24 months to evaluate the effect of febuxostat on echocardiographic parameters.
I
Intervention
Febuxostat (10 mg, 20 mg, or 40 mg daily) added to appropriate lifestyle modification for 24 months.
C
Comparator
Appropriate lifestyle modification for hyperuricemia (healthy diet and exercise therapy) without febuxostat.
O
Outcome
Comparison of the changes in the E/e' (ratio of peak early diastolic transmitral flow velocity to peak early diastolic mitral annular velocity) between the two groups from baseline to 24 months.surrogate
Main Result
Absolute Event Rate: -0.13% vs 0.15%
p-value: p=0.010
Febuxostat treatment over 24 months may prevent the progression of left ventricular diastolic dysfunction in patients with asymptomatic hyperuricemia.
Limitations
- Post-hoc subanalysis with echocardiography not performed in all subjects, leading to a small sample size.
- Advanced diastolic functional markers (e.g., strain imaging) were not performed.
- Included only Japanese patients, limiting generalizability.
- Small sample size made it statistically difficult to evaluate the relationship between doses and echocardiographic parameters.
- Subanalysis of the PRIZE study
- Echocardiography not performed in all subjects
- Small sample size
- Included only Japanese patients
- Difficult to evaluate the relationship between doses and echocardiographic parameters
- Lack of advanced diastolic parameters like global longitudinal strains
Cite This Study
Kusunose et al. (2021) conducted an RCT in Asymptomatic hyperuricemia (n=65). Febuxostat vs. Appropriate lifestyle modification was evaluated on Change in E/e' from baseline to 24 months (p=0.010). Febuxostat treatment for 24 months significantly prevented the worsening of left ventricular diastolic function, as measured by the change in E/e', compared to lifestyle modification alone in patients with asymptomatic hyperuricemia.
View Full Paper
Ask AI
Bookmark
Share